News
Public · Published
Rhythm Amends LG Chem Deal, Secures Up To $750 Million Financing For Obesity Pipeline
Rhythm Pharmaceuticals amended its licensing agreement with LG Chem for bivamelagon, an experimental oral therapy for rare obesity disorders. Rhythm will pay LG Chem $350 million in fixed payments over four years and secured access to up to $750 million in financing.
Published:
Updated:
What happened
Rhythm Pharmaceuticals amended its licensing agreement with LG Chem for bivamelagon, an experimental oral therapy for rare obesity disorders. Rhythm will pay LG Chem $350 million in fixed payments over four years and secured access to up to $750 million in financing.
Confirmed
Global impact / market context
The revised deal swaps older sales-based royalty payments for a flat 1% royalty, which may make future costs more predictable for investors. The new loan gives Rhythm cash available to fund bivamelagon and its wider obesity drug portfolio.
Analyst inference
Obesity treatments have drawn strong investor interest. Rhythm is tying part of the deal to reaching $3 billion in yearly portfolio sales, so the agreement shares both cost savings and future upside with LG Chem rather than placing all risk on Rhythm.
Analyst inference
What to watch
- Rhythm must make $350 million in fixed payments to LG Chem over the next four years, so watch how these scheduled cash outflows affect the company's spending plans. Confirmed
- The amended deal adds a possible $200 million milestone payment if annual global net sales across the MC4R portfolio reach $3 billion, a target investors should track. Proposed
- The 1% royalty starts in 2029 or at first commercial sales of bivamelagon, whichever comes first, so watch bivamelagon's approval timeline since it changes when royalties begin. Analyst inference
Evidence
- Original source link unavailable